Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 8:15:20420188231224233.
doi: 10.1177/20420188231224233. eCollection 2024.

Glycogen storage disease type III: a mixed-methods study to assess the burden of disease

Ayla Evins  1 , Jill Mayhew  2 , Tricia Cimms  2 , Julie Whyte  3 , Kathy Vong  3 , Elizabeth Hribal  3 , Christopher J Evans  3 , Andrew Grimm  2
Affiliations

Glycogen storage disease type III: a mixed-methods study to assess the burden of disease

Ayla Evins et al. Ther Adv Endocrinol Metab. .

Abstract

Background: Glycogen storage disease type III (GSD III) is a rare inherited disorder that results from a glycogen debranching enzyme deficiency.

Objectives: The purpose of this research was to collect data on the signs, symptoms, and impacts of GSD III from the perspective of adult patients and caregivers of individuals with GSD III.

Design: Online survey and qualitative interviews.

Methods: Following institutional review board approval, adult patients and caregivers of children with GSD III were recruited through advocacy networks and clinical sites. If eligible, participants were consented, screened, and sent a survey and/or participated in a 60-min interview. The survey and interview included questions about family history, diagnosis, signs and symptoms, impacts, and management of GSD III. Conceptual models were developed following the analysis of results.

Results: In all, 29 adults and 46 caregivers completed the online survey and/or the interviews with 73 survey and 19 interview respondents. Adults and caregivers reported digestive, musculoskeletal, growth and physical appearance, and cardiac signs and symptoms. Liver conditions were reported by most respondents (83%). Adults and caregivers frequently reported impacts such as difficulty keeping up with peers (77%) and difficulty exercising/difficulty with physical activity (53%). Hypoglycemia was frequently reported in both adults and children, with more than half reporting hospitalizations due to hypoglycemia. Caregivers focused on hypoglycemia when reporting signs/symptoms that most interfere with their child's life and prevention of hypoglycemia as a desired outcome for an effective therapy. Adults most often reported muscle weakness as a top interfering symptom and the most important goal of a potential therapy. Impacts were also reported in activities of daily living, cognitive, emotional, work/school, and sleep domains.

Conclusion: Individuals with GSD III experience a broad spectrum of symptoms and disease impacts. There is an unmet need for therapies that improve metabolic control, reduce the burden of dietary management, reduce fatigue and liver problems, and improve muscle strength and function.

Keywords: conceptual model; glycogen storage disease type III; mixed methods; qualitative research; rare disease.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
GSD III defining signs/symptoms conceptual model. Some signs/symptoms are included under multiple organ systems. GSD III, glycogen storage disease type III.
Figure 2.
Figure 2.
GSD III defining impacts conceptual model. GSD III, glycogen storage disease type III.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Cardiovascular involvement in glycogen storage diseases.
    Pinós T, Cubbon RM, Santalla A, Fiuza-Luces C, Santos-Lozano A, Martín MA, Arenas J, Nielsen J, Ørtenblad N, Lucia A. Pinós T, et al. Nat Rev Cardiol. 2025 Jun 5. doi: 10.1038/s41569-025-01171-w. Online ahead of print. Nat Rev Cardiol. 2025. PMID: 40473899 Review.
  • Galectin-3: a novel biomarker of glycogen storage disease type III.
    Rossiaud L, Miagoux Q, Benabides M, Reiss O, Jauze L, Jarrige M, Polvèche H, Malfatti E, Laforêt P, Ronzitti G, Nissan X, Hoch L. Rossiaud L, et al. Cell Death Discov. 2025 Apr 14;11(1):173. doi: 10.1038/s41420-025-02452-6. Cell Death Discov. 2025. PMID: 40229243 Free PMC article.

References

    1. Derks TGJ, Smit GPA. Dietary management in glycogen storage disease type III: what is the evidence? J Inherit Metab Dis 2015; 38: 545–550. - PubMed
    1. Rousseau-Nepton I, Okubo M, Grabs R, et al. A founder AGL mutation causing glycogen storage disease type IIIa in Inuit identified through whole-exome sequencing: a case series. CMAJ 2015; 187: E68–E73. - PMC - PubMed
    1. Endo Y, Horinishi A, Vorgerd M, et al. Molecular analysis of the AGL gene: heterogeneity of mutations in patients with glycogen storage disease type III from Germany, Canada, Afghanistan, Iran, and Turkey. J Hum Genet 2006; 51: 958–963. - PubMed
    1. Parvaria R, Mosesb S, Shen J, et al. A single-base deletion in the 3′-coding region of glycogen-debranching enzyme is prevalent in glycogen storage disease type IIIA in a population of North African Jewish patients. Eur J Hum Genet 1997; 5: 266–270. - PubMed
    1. Chen MA, Weinstein DA. Glycogen storage diseases: diagnosis, treatment and outcome. Transl Sci Rare Dis 2016; 1: 45–72.

LinkOut - more resources